Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23662296 | 0.83 | BRD4 (0.52) | BRD4MEN1KMT2AAHRTP53 | |
| SCHEMBL15825941 | 0.78 | BRD4 (0.47) | BRD4MEN1KMT2ATP53MAPT | |
| SCHEMBL15825879 | 0.77 | BRD4 (0.47) | BRD4MEN1KMT2ATP53MAPT | |
| SCHEMBL21651855 | 0.77 | ALOX15 (0.51) | BRD4MEN1KMT2AMAPT | |
| SCHEMBL15825403 | 0.75 | BRD4 (0.45) | BRD4MEN1KMT2ATP53MAPT | |
| SCHEMBL7174420 | 0.74 | MEN1 (0.44) | BRD4HTR2CMEN1KMT2APGR | |
| SCHEMBL17374035 | 0.73 | BRD4 (0.41) | BRD4MEN1KMT2AMAPT | |
| SCHEMBL18064421 | 0.73 | BRD4 (0.41) | BRD4MEN1KMT2AMAPT | |
| SCHEMBL21651800 | 0.72 | OPRL1 (0.54) | BRD4MEN1KMT2AMAPT | |
| SCHEMBL16371457 | 0.71 | BRD4 (0.42) | BRD4MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0657166-B1 | Combination containing a quinoxaline and a nucleoside | AVENTIS PHARMA GMBH (DE) | 2003-04-09 | — | — | EP | disclosed |
| US-6369057-B1 | VIRICIDES, IN PARTICULAR AGAINST RETROVIRUSES, HUMAN IMMUNODEFICIENCY VIRUS (HIV) | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| EP-0509398-B1 | Quinoxalines, process for their preparation and their use | AVENTIS PHARMA GMBH (DE) | 2001-09-19 | — | — | EP | disclosed |
| EP-0657166-A1 | Combination containing a quinoxaline and a nucleoside | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-06-14 | — | — | EP | disclosed |
| EP-0509398-A1 | Quinoxalines, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-10-21 | — | — | EP | disclosed |